Molekularpathologie des nichtkleinzelligen Lungenkarzinoms: aktuelle und kommende Biomarker DOI Creative Commons
Helen Pasternack,

Jutta Kirfel

Deleted Journal, Год журнала: 2025, Номер unknown

Опубликована: Апрель 3, 2025

In the classification of lung cancer, basic division into small cell and non-small carcinomas continues to apply. Despite same histological subtyping, it is known that there are defined genetic changes in tumor cells significantly determine growth as "drivers", so their blockade can influence clinical course. Thus, last 10 years, treatment cancer has been increasingly supplemented by establishment tumor-specific targeted drugs immunomodulatory approaches. This development led differentiated individualized approaches treatment. Pathology especially molecular pathological diagnostics play a central role here, an increasing number biomarkers must be examined.

Язык: Английский

Chirurgie du cancer bronchique non à petites cellules de stade précoce DOI
Pierre Mordant

Bulletin de l Académie Nationale de Médecine, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Процитировано

0
A computer-aided, carrier-free drug delivery system with enhanced cytotoxicity and biocompatibility: a universal model for multifunctional lung cancer therapy DOI
Zhonglei Wang,

Wenjing Xu,

Shizeng Lei

и другие.

Colloids and Surfaces B Biointerfaces, Год журнала: 2025, Номер 250, С. 114557 - 114557

Опубликована: Фев. 9, 2025

Язык: Английский

Процитировано

0
An electrochemiluminescence biosensor based on metal porphyrin luminophore and covalent organic framework for the sensitive detection of ctDNA in non-small cell lung cancer DOI
Min Qing, Fu Lin,

Xuemei Hu

и другие.

Talanta, Год журнала: 2025, Номер 288, С. 127734 - 127734

Опубликована: Фев. 11, 2025

Язык: Английский

Процитировано

0
Prognostic Value of Tumor Dissemination (Dmax) Derived from Basal 18F-FDG Positron Emission Tomography/Computed Tomography in Patients with Advanced Non-Small-Cell Lung Cancer DOI Creative Commons
Sara Pellegrino, Rosa Fonti, Rocco Morra

и другие.

Biomedicines, Год журнала: 2025, Номер 13(2), С. 477 - 477

Опубликована: Фев. 15, 2025

Objectives: The aim of the present study was to test whether a parameter reflecting tumor dissemination (Dmax), derived from basal 18F-FDG PET/CT, may predict clinical outcome in patients with advanced non-small-cell lung cancer (NSCLC). Methods: A total 78 (55 men, 23 women) stage III and IV NSCLC who had undergone whole-body PET/CT scan at diagnosis were included this study. Imaging parameters primary tumors along MTV (MTVTOT) TLG (TLGWB) all malignant lesions determined. Moreover, largest distance between two avid (Dmax) each patient measured. Univariate multivariate analyses imaging variables performed followed by overall survival (OS) curves. Results: 441 analyzed, including tumors, 174 metastatic lymph nodes, 189 distant metastases. In average values SUVmax, SUVmean, MTV, 11.80 ± 5.73, 5.37 2.09, 60.61 102.57 mL, 340.36 558.40 g, respectively. mean value Dmax 29.98 20.98 cm, whereas MTVTOT TLGWB 155.90 176.94 mL 851.08 1032.17 univariate analysis, OS predicted (p = 0.0145), 0.0518), 0.0031), 0.0130), only retained model (χ2 7.3130, p 0.0068). particular, high indicates worse prognosis. combination able improve prognostic stratification stages NSCLC. Conclusions: Dmax, throughout body, can patients.

Язык: Английский

Процитировано

0
REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC DOI Creative Commons
John V. Heymach, Helena A. Yu, Benjamin Besse

и другие.

Future Oncology, Год журнала: 2025, Номер 21(5), С. 549 - 556

Опубликована: Фев. 16, 2025

There remains a significant unmet need for effective and tolerable treatments patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations in the first-line setting. First later generation EGFR tyrosine kinase inhibitors (TKIs) have shown efficacy common mutations; however, their effectiveness against ex20ins is limited, platinum-based chemotherapy part of standard care. Data suggest that combining offers promise ex20ins-mutated NSCLC. REZILIENT3 an ongoing phase III study evaluating safety zipalertinib (an orally available, irreversible EGFR-TKI) plus standard-of-care alone previously untreated nonsquamous NSCLC mutations.

Язык: Английский

Процитировано

0
Rutecarpine Suppresses Non‐Small Cell Lung Cancer Progression Through Activating the STING Pathway and Elevating CD8+ T Cells DOI

Zebo Jiang,

Qiang He,

Liping Kang

и другие.

Chemical Biology & Drug Design, Год журнала: 2025, Номер 105(2)

Опубликована: Фев. 1, 2025

ABSTRACT Globally, non‐small cell lung cancer (NSCLC) is the primary cause of cancer‐related deaths. Rutecarpine (RUT), a quinazolinocarboline alkaloid that naturally occurring and present in Chinese medicinal herbs, has been shown to have anticancer properties several lines. However, specific antitumor mechanisms RUT NSCLC remain unclear. This study demonstrates induces apoptosis significantly reduces viability effect achieved by stimulating intracellular ROS production, leading mitochondrial dysfunction. The decreased observed with treatment attributed elimination through suppression N‐acetylcysteine (NAC). Furthermore, therapy elevated production CXCL10 CCL5 lines markedly activated STING pathway cells. Mechanistically, substantially levels PD‐L1 protein Notably, vivo experiments demonstrated inhibits mouse tumor growth mice, exhibiting anti‐tumor activity elevating CD8 + T These findings strongly support as promising anti‐cancer drug for NSCLC.

Язык: Английский

Процитировано

0
A multi-stage fusion deep learning framework merging local patterns with attention-driven contextual dependencies for cancer detection DOI
Hatice Çatal Reis, Veysel Turk

Computers in Biology and Medicine, Год журнала: 2025, Номер 189, С. 109916 - 109916

Опубликована: Март 6, 2025

Язык: Английский

Процитировано

0
Establishment and validation of a survival prediction model for stage IV non-small cell lung cancer: a real-world study DOI Creative Commons

Keao Zheng,

Junyan Zhang,

Xu Tingting

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Март 6, 2025

The aim of this study is to develop and validate a predictive model for predicting survival in individual advanced non-small cell lung cancer patients by integrating basic patient information clinical data. A total 462 with collected from Shanxi Cancer Hospital were randomly assigned (in 7:3 ratio) training cohort an internal validation cohort. Independent factors affecting patients' 3-year screened models created using single-factor followed multifactor Cox regression analysis. Evaluate the performance consistency index (C-index), calibration curves, receiver operating characteristic curves (ROC) decision curve analysis (DCA). who received chemotherapy alone those combined immunotherapy statistically paired propensity score matching between two groups, subgroup analyses performed among variables. better prognostic was nomogram chart visualizing drawn. Based on median risk cohort, all individuals categorized into high- low-risk high-risk group having worse OS both cohorts (P<0.05). results showed that versus NSCLC affected OS. developed predict cancer. demonstrated superior alone.

Язык: Английский

Процитировано

0
NSUN4 Facilitates the Activity of Oncogenic Protein CDC20 to Promote NSCLC Development by Mediating m5C Modification of CDC20 mRNA DOI Creative Commons
Zhilong Li,

Wu Xianzhen

Thoracic Cancer, Год журнала: 2025, Номер 16(5)

Опубликована: Март 1, 2025

5-methylcytosine (m5C) methylation is the crucial posttranscriptional modification of RNA. NSUN4, a methyltransferase for m5C methylation, contributes to lung tumorigenesis. Here, we determined precise action NSUN4 on development non-small cell cancer (NSCLC). and CDC20 mRNA expression was detected by quantitative PCR. Western blot immunohistochemistry were used analysis protein expression. Cell growth, apoptosis, invasiveness, migratory ability, stemness potential evaluated colony formation, flow cytometry, transwell, sphere formation assays. The influence in analyzed using RNA immunoprecipitation (RIP) assay Actinomycin D (Act D) treatment. Subcutaneous xenograft studies performed analyze function vivo. In human NSCLC tumors lines, levels upregulated. inhibition diminished stemness, ability vitro, while increase had opposite effects. A positive association between observed samples. Mechanistically, enhanced stability through modification. depletion significantly counteracted NSUN4-driven phenotype alterations vitro. Additionally, impeded growth A549 subcutaneous xenografts Our findings identify pro-tumorigenic property NSUN4/CDC20 cascade NSCLC. Targeting novel may be promising way combating this deadly disease.

Язык: Английский

Процитировано

0
The Role of Yes‐Associated Protein in Inflammatory Diseases and Cancer DOI Creative Commons
Bing Zhong, Jintao Du,

Feng Liu

и другие.

MedComm, Год журнала: 2025, Номер 6(3)

Опубликована: Март 1, 2025

Yes-associated protein (YAP) plays a central role in the Hippo pathway, primarily governing cell proliferation, differentiation, and apoptosis. Its significance extends to tumorigenesis inflammatory conditions, impacting disease initiation progression. Given increasing relevance of YAP disorders cancer, this study aims elucidate its pathological regulatory functions these contexts. Specifically, we aim investigate involvement molecular mechanisms various diseases cancers. We particularly focus on how activation, whether through Hippo-dependent or independent pathways, triggers release inflammation mediators respiratory, cardiovascular, digestive conditions. In not only promotes tumor proliferation differentiation but also modulates immune microenvironment, thereby fostering metastasis Additionally, provide an overview current YAP-targeted therapies. By emphasizing YAP's enhance our understanding protein's pivotal processes, intricate related diseases, contribute future drug development strategies targeting YAP.

Язык: Английский

Процитировано

0